Granisetron Hydrochloride

CHEMBL1237080 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
348.9 g/mol
LogP
Phase
4

A hydrochloride salt form of granisetron, a 5-HT3 antagonist antiemetic used to prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The hydrochloride salt form is used in both oral tablets and injectable preparations. It provides effective antiemetic coverage, particularly for acute chemotherapy-induced nausea occurring within the first 24 hours of treatment.

น้ำหนักโมเลกุล

348.9000 g/mol

TPSA

50.20 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2.Cl

InChI

InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H

Molecular Formula

C18H25ClN4O

HBD / HBA

2 / 3

พันธะที่หมุนได้

2

อะตอมหนัก

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A hydrochloride salt form of granisetron, a 5-HT3 antagonist antiemetic used to prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The hydrochloride salt form is used in both oral tablets and injectable preparations. It provides effective antiemetic coverage, particularly for acute chemotherapy-induced nausea occurring within the first 24 hours of treatment.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Granisetron Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237080. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 65264. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.